NCMM Research Groups

The Centre for Molecular Medicine Norway consists of several research groups, lead by internationally recruited team leaders.

Photo from the lab

Photo: Trond Isaksen/UiO

Esguerra Group

Our research team is focused on exploring the fundamental mechanisms underlying brain function in health and disease.

Gözen Group

In our laboratory we use soft biomaterials, such as lipid membranes, to mimic the behavior of living cells.

Haapaniemi Group

Our group focuses on developing targeted therapies for rare immunological conditions, such as primary immunodeficiency diseases and immunological conditions of unknown origin.

Kuijjer Group

Our group aims to solve fundamental biological questions through the development of new methods in computational and systems biology.

Lopez-Aviles Group

Our group studies the mechanisms controlling progression through the cell cycle. More specifically, we focus on the study of mitotic exit and the involvement of protein phosphatases in this transition, using the fission yeast Schizosaccharomyces pombe as a model organism.

Luecke Group

Our group focuses on the structure-function investigations of integral membrane proteins.

Mathelier Group

We aim to develop cutting-edge bioinformatics tools with immediate application to real-life biological problems, such as gene expression regulation and cancer.

Saarela Group

Our research focuses on improving the understanding of biological pathways and pathogenic mechanisms behind rare and common immune diseases, especially primary immune deficiencies and multiple sclerosis, and utilizing the new knowledge to benefit patients.

Sekulic Group

Our research group is using modern biophysical methods in combination with structural - and cell biology to answer important questions in the field of chromatin biology.

Staerk Group

Our research team is generally interested in understanding molecular processes during normal and malignant hematopoiesis.

Waszak Group

Our group is working towards the development of precision medicine strategies for pediatric brain cancer patients.